Pulmitac
Pulmitac Uses, Dosage, Side Effects, Food Interaction and all others data.
Pulmitac is an adrenergic β2 receptor agonist which predominantly stimulates β2 receptor, thus producing relaxation of bronchial smooth muscle, inhibition of release of endogenous spasmogens, inhibition of edema caused by endogenous mediators & increased mucocilliary clearance.
Pulmitac is a long acting beta2-adrenoceptor agonist used in the treatment of asthma. It is a prodrug of terbutaline. Pulmitac causes smooth muscle relaxation, resulting in dilation of bronchial passages.
| Trade Name | Pulmitac |
| Generic | Bambuterol |
| Bambuterol Other Names | Bambuterol, bambutérol, Bambuterolum |
| Weight | 10mg, 20mg |
| Type | Tablet |
| Formula | C18H29N3O5 |
| Weight | Average: 367.44 Monoisotopic: 367.210721053 |
| Groups | Investigational |
| Therapeutic Class | Short-acting selective β2-adrenoceptor stimulants |
| Manufacturer | Platinum Pharmaceuticals (pvt,) Ltd, |
| Available Country | Pakistan |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Pulmitac is used for Bronchial asthma, chronic bronchitis, emphysema & other lung diseases where bronchospasm is a complicating factor.
Pulmitac is also used to associated treatment for these conditions: Bronchial Asthma, Bronchospasm, Chronic Bronchitis, Emphysema
How Pulmitac works
The pharmacologic effects of bambuterol are at least in part attributable to stimulation through beta-adrenergic receptors (beta 2 receptors) of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic AMP. Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
Dosage
Pulmitac dosage
Adult or Elderly: The recommended initial dose 10 mg. The dose may be increased to 20 mg after 1-2 weeks depending on the clinical effect.
Children 2-5 years:The recommended normal dose 10 mg (10 ml syrup).
Children 6-12 years:The recommended normal dose 10 mg (10 ml syrup). The dose may be increased to 20 mg.
Side Effects
Common side effects are fatigue, nausea, palpitation, headache, dizziness & tremor.
Precaution
Reduce the dose in renal impairment, avoid in cirrhosis and severe hepatic impairment. Caution should be observed in patients with severe cardiovascular disorder, such as ischaemic heart disease, tachyarrhythmias or severe heart failure.
Interaction
Succinylcholin, MAOIs (monoamine oxidase inhibitors), β2-blockers, corticosteroids, diuretics, muscle relaxants, sympathomimetic xanthine derivatives. Pulmitac may partly or totally inhibit the effect of β-blockers.
Elimination Route
Bioavailability is 20% following oral administration.
Half Life
13 hours for bambuterol and 21 hours for the primary active metabolite terbutaline.
Pregnancy & Breastfeeding use
Pregnant women: There is no definite evidence of ill consequence during pregnancy. Nevertheless, the drug should not be used during the first trimester of pregnancy, unless the expected benefit is thought to outweigh any possible risk to the fetus.
Lactating mother: It is excreted in breast milk. So, patients taking this drug should not breast-feed.
Contraindication
Pulmitac is contraindicated in hepatic impairment, liver cirrhosis or severely impaired liver function.
Special Warning
Impaired renal function (GFR 50 ml/min): The recommended starting dose is 5 mg, which may be increased to 10 mg after one to two weeks, depending on the clinical effect.
Impaired hepatic function: Not recommended because of unpredictable conversion to terbutaline.
Storage Condition
Keep away from light, store in a cool and dry place. Keep out of reach of children.
Innovators Monograph
You find simplified version here Pulmitac
Pulmitac contains Bambuterol see full prescribing information from innovator Pulmitac Monograph, Pulmitac MSDS, Pulmitac FDA label
